A Study of RNA Vaccine (BNT162b2) Against COVID-19 in Healthy Pregnant Participants
A Phase 2/3, Placebo-Controlled, Randomized, Observer-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Category & Conditions: Vaccine-related Conditions
Medicine: PF-07302048 (BNT162)
ClinicalTrials.gov Identifier (NCT): NCT04754594
Protocol ID: C4591015
Open Plain Language Summary Result:
Click here